Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses

Clinical Medicine and Research

Volumn 9, Issue 3-4, 2011, Pages 119-124

  Burmester, James K ^a   Berg, Richard L ^a   Glurich, Ingrid ^a   Yale, Steven H ^a   Schmelzer, John R ^a   Caldwell, Michael D ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

CYP4F2; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

WARFARIN;

ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DNA SEQUENCE; DRUG DOSE REGIMEN; DRUG MEGADOSE; GENE; GENE FUNCTION; GENETIC CODE; GENETIC VARIABILITY; HEREDITY; HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VKORCI GENE;

ANTICOAGULANTS; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOEMBOLISM; WARFARIN;

EID: 81355122980     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2011.951     Document Type: Article

References (24)

1. Glurich I, Burmester JK, Caldwell MD. Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev 2010;15:239-248.
2. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999;59:635-646.
3. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-1097.
4. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007;5:8-16.
5. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.
6. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-2293.
7. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008;111:4106-4112.
8. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764.
9. Daly AK. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 2009;1:10.
10. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-649.
11. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ, Mumford AD. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008;6:1663-1670.
12. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005;93:23-26.
13. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009;75:1337-1346.
14. Sagrieya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A, Altman RB. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010;20:407-413.
15. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004;14(8):539-547.
16. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med 2004;10:299-302.
17. Ainle FN, Mumford A, Tallon E, McCarthy D, Murphy K. A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfrin resistance. Ir J Med Sci 2008;177:159-161.
18. Wilms EB, Touw DJ, Conemans JM, Veldkamp R, Hermans M. A new VKORC1 allelic variant (p. Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost 2008;6:1224-1226.
19. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007;109:2477-2480.
20. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopean individuals. Blood 2008;111:3903-3904.
21. Zhang JE, Jorgensen AL, Alfirevic A, Williamson PR, Toh CH, Park BK, Pirmohamed M. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009;19:781-789.
22. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022-1027.
23. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009;18:3758-3768.
24. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.